Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia

Luke W. Bonham, Natasha Z. R. Steele, Celeste M. Karch, Iris Broce, Ethan G. Geier, Natalie Wen, Parastoo Momeni, John Hardy, Zachary Miller, Maria Luisa Gorno‐Tempini, Christopher P. Hess, Patrick A. Lewis, Bruce L. Miller, William W. Seeley, Claudia Manzoni, Rahul S. Desikan, Sergio E. Baranzini, Raffaele Ferrari, Jennifer S. Yokoyama, D. G. Hernandez, M. A. Nalls, Jonathan D. Rohrer, Adaikalavan Ramasamy, John B. Kwok, Carol Dobson‐Stone, Peter R. Schofield, Glenda M. Halliday, John R. Hodges, Olivier Piguet, Lauren Bartley, Emma E. Thompson, Eric Haan, Isabel Hernández, Agustı́n Ruiz, Merçé Boada, B. Borroni, Alessandro Padovani, Carlos Cruchaga, Nigel J. Cairns, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Gianluigi Forloni, Diego Albani, Daniela Galimberti, Chiara Fenoglio, María Serpente, Elio Scarpini, Jordi Clarimón, Alberto Lleó, Rafael Blesa, Maria Landqvist Waldö, Karin Nilsson, Christer Nilsson, Ian R. Mackenzie, Ging‐Yuek Robin Hsiung, David Mann, Jordan Grafman, Christopher M. Morris, Johannes Attems, Timothy D. Griffiths, Ian G. McKeith, Alexandria Thomas, Pietro Pietrini, Edward D. Huey, Eric M. Wassermann, Atik Baborie, Evelyn Jaros, Michael Tierney, Pau Pástor, Cristina Razquín, Sara Ortega‐Cubero, Elena Alonso, Robert Perneczky, Janine Diehl‐Schmid, Panagiotis Alexopoulos, Alexander Kurz, Innocenzo Rainero, Elisa Rubino, Lorenzo Pinessi, E. Rogaeva, Peter St George‐Hyslop, Giacomina Rossi, Fabrizio Tagliavini, Giorgio Giaccone, James B. Rowe, Johannes C. M. Schlachetzki, James Uphill, J. Collinge, Simon Mead, Adrian Danek, Vivianna M. Van Deerlin, Murray Grossman, John Q. Trojanowski, Julie van der Zee, Marc Cruts, Christine Van Broeckhoven, Stefano F. Cappa, Isabelle Leber, Didier HannequinScientific 2019 · DOI

Abstract

The semantic variant of primary progressive aphasia (svPPA) is a clinical syndrome characterized by neurodegeneration and the progressive loss of semantic knowledge. Unlike many other forms of frontotemporal lobar degeneration (FTLD), svPPA exhibits a highly consistent underlying pathology composed of TDP-43, a regulator of RNA and DNA transcription metabolism. Previous genetic studies of svPPA have been limited by small sample sizes and a paucity of common risk variants. Despite these challenges, svPPA's relatively homogenous clinicopathologic phenotype makes it an ideal investigative model for examining genetic processes that drive neurodegenerative disease.

In this study, researchers utilized GWAS metadata, tissue samples from pathologically confirmed FTLD, and in silico techniques to identify and characterize protein interaction networks associated with svPPA risk. The study identified 64 svPPA risk genes that interact at the protein level. These genes represent critical regulators of RNA metabolism and cell death, such as SMAD proteins and NOTCH1, and many are involved in TDP-43 metabolism. Contrary to the conventional notion that svPPA has few genetic risk factors, these analyses demonstrate that svPPA risk is complex and polygenic, likely driven by multiple common variants working in combination to promote neurodegeneration.

Introduction

Semantic variant primary progressive aphasia (svPPA) presents a unique puzzle in neurodegenerative research. While patients experience a remarkably consistent decline in semantic memory—the ability to understand words and identify objects—the genetic underpinnings of the disease have remained largely opaque. Unlike other forms of frontotemporal dementia, svPPA rarely follows a clear familial inheritance pattern, leading to a long-held belief that the disorder might be driven primarily by non-genetic factors.

However, a new study published in Scientific Reports challenges this paradigm. By moving beyond the search for single "smoking gun" mutations and instead analyzing complex gene networks, researchers have revealed that svPPA is a polygenic disorder deeply rooted in the dysregulation of RNA metabolism and programmed cell death pathways.

Methodology

The researchers employed a multi-step bioinformatic pipeline to bridge the gap between raw genetic data and functional biological insights:

  • Gene-Based Association: Using the VEGAS tool, the team aggregated individual SNP (single nucleotide polymorphism) data into gene-level p-values.
  • Protein Interaction Network (PIN) Analysis: Significant genes were mapped onto a background network of known protein-protein interactions (derived from the iRefIndex database) using the PINBPA package.
  • Hub Identification: The study utilized weighted protein-protein interaction network analysis (W-PPI-NA) to identify "inter-interactome hubs" (IIHs)—critical proteins that act as bridges within the risk network.
  • Functional Enrichment: Pathway analysis was performed using Reactome and Gene Ontology (GO) to identify overrepresented biological themes.
  • Transcriptomic Validation: The findings were validated by checking the differential expression of risk genes in diseased brain tissue (GSE13162) compared to healthy controls.

Datasets

The study leveraged the IFGC Phase-1 GWAS (2,154 FTD spectrum cases, including 361 svPPA cases) and the Braineac database to identify the top brain regions expressing the identified risk genes.

Key Results and Insights

The 64-Gene Risk Network

The core finding of the study is a significant network of 64 risk genes connected by 81 protein-level interactions. This network was found to be statistically robust, appearing in the top 10th percentile for both node and edge density during permutation testing.

RNA Metabolism and the TDP-43 Connection

While the TARDBP gene (which encodes the TDP-43 protein) was not a top hit itself, the identified network is rich with its functional partners. This suggests that genetic variation in the regulators of TDP-43 metabolism—rather than the protein itself—is what drives the characteristic pathology of svPPA. The strongest signals were found in pathways related to RNA transcription and processing, aligning with TDP-43's known biological role.

Critical Signaling Hubs

The study identified several "inter-interactome hubs" that act as central nodes in the disease network:

  • SMAD Proteins: SMAD3 and SMAD4 were identified as central hubs. These are involved in signaling pathways that regulate neuronal stability and apoptosis.
  • Pathway Enrichment: Specific pathways showed massive fold enrichment, including Activin beta signaling (74.46x), Pre-NOTCH transcription (66.75x), and SMAD transcriptional activity (56.11x).

Tissue Validation

Biological relevance was confirmed by the fact that 15 of the 64 network genes (including HNF4A, PSEN1, and NR5A1) showed significant differential expression in actual diseased brain tissue samples.

Discussion and Limitations

This research marks a significant shift in how we view svPPA genetics. By demonstrating that risk is driven by a "complex and polygenic" network of common variants, the study provides a genetic basis for a syndrome previously thought to be sporadic.

However, several limitations remain. The sample size of 361 svPPA cases, while large for such a rare subtype, is still small for GWAS standards. Additionally, network analysis is inherently biased toward well-studied proteins already present in databases. Most importantly, these findings identify associations; further molecular and animal-model studies are required to prove that these specific gene variations cause the neurodegeneration observed in patients.

Conclusion

The discovery of a 64-gene network centered on RNA metabolism and cell death provides a new roadmap for understanding svPPA. These findings suggest that therapeutic strategies targeting the regulators of TDP-43 and SMAD signaling may hold promise for treating this devastating loss of semantic knowledge.

Summary updated

Abstract

The semantic variant of primary progressive aphasia (svPPA) is a clinical syndrome characterized by neurodegeneration and progressive loss of semantic knowledge. Unlike many other forms of frontotemporal lobar degeneration (FTLD), svPPA has a highly consistent underlying pathology composed of TDP-43 (a regulator of RNA and DNA transcription metabolism). Previous genetic studies of svPPA are limited by small sample sizes and a paucity of common risk variants. Despite this, svPPA's relatively homogenous clinicopathologic phenotype makes it an ideal investigative model to examine genetic processes that may drive neurodegenerative disease. In this study, we used GWAS metadata, tissue samples from pathologically confirmed frontotemporal lobar degeneration, and in silico techniques to identify and characterize protein interaction networks associated with svPPA risk. We identified 64 svPPA risk genes that interact at the protein level. The protein pathways represented in this svPPA gene network are critical regulators of RNA metabolism and cell death, such as SMAD proteins and NOTCH1. Many of the genes in this network are involved in TDP-43 metabolism. Contrary to the conventional notion that svPPA is a clinical syndrome with few genetic risk factors, our analyses show that svPPA risk is complex and polygenic in nature. Risk for svPPA is likely driven by multiple common variants in genes interacting with TDP-43, along with cell death,x` working in combination to promote neurodegeneration.
BibTeX
@inproceedings{bonham2019genetic,
  author = {Luke W. Bonham and Natasha Z. R. Steele and Celeste M. Karch and Iris Broce and Ethan G. Geier and Natalie Wen and Parastoo Momeni and John Hardy and Zachary Miller and Maria Luisa Gorno‐Tempini and Christopher P. Hess and Patrick A. Lewis and Bruce L. Miller and William W. Seeley and Claudia Manzoni and Rahul S. Desikan and Sergio E. Baranzini and Raffaele Ferrari and Jennifer S. Yokoyama and D. G. Hernandez and M. A. Nalls and Jonathan D. Rohrer and Adaikalavan Ramasamy and John B. Kwok and Carol Dobson‐Stone and Peter R. Schofield and Glenda M. Halliday and John R. Hodges and Olivier Piguet and Lauren Bartley and Emma E. Thompson and Eric Haan and Isabel Hernández and Agustı́n Ruiz and Merçé Boada and B. Borroni and Alessandro Padovani and Carlos Cruchaga and Nigel J. Cairns and Luisa Benussi and Giuliano Binetti and Roberta Ghidoni and Gianluigi Forloni and Diego Albani and Daniela Galimberti and Chiara Fenoglio and María Serpente and Elio Scarpini and Jordi Clarimón and Alberto Lleó and Rafael Blesa and Maria Landqvist Waldö and Karin Nilsson and Christer Nilsson and Ian R. Mackenzie and Ging‐Yuek Robin Hsiung and David Mann and Jordan Grafman and Christopher M. Morris and Johannes Attems and Timothy D. Griffiths and Ian G. McKeith and Alexandria Thomas and Pietro Pietrini and Edward D. Huey and Eric M. Wassermann and Atik Baborie and Evelyn Jaros and Michael Tierney and Pau Pástor and Cristina Razquín and Sara Ortega‐Cubero and Elena Alonso and Robert Perneczky and Janine Diehl‐Schmid and Panagiotis Alexopoulos and Alexander Kurz and Innocenzo Rainero and Elisa Rubino and Lorenzo Pinessi and E. Rogaeva and Peter St George‐Hyslop and Giacomina Rossi and Fabrizio Tagliavini and Giorgio Giaccone and James B. Rowe and Johannes C. M. Schlachetzki and James Uphill and J. Collinge and Simon Mead and Adrian Danek and Vivianna M. Van Deerlin and Murray Grossman and John Q. Trojanowski and Julie van der Zee and Marc Cruts and Christine Van Broeckhoven and Stefano F. Cappa and Isabelle Leber and Didier Hannequin},
  title = {{Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia}},
  booktitle = {Scientific},
  year = {2019},
  doi = {10.1038/s41598-019-46415-1},
}
Figure